<DOC>
	<DOCNO>NCT00086580</DOCNO>
	<brief_summary>This Phase 3 , prospective , multicenter , open-label , randomize , control study evaluate compare efficacy safety fludarabine plus alemtuzumab versus fludarabine alone second-line therapy patient relapse refractory B-cell chronic lymphocytic leukemia ( B-CLL ) . Patients meet eligibility criterion sign inform consent document may enter study .</brief_summary>
	<brief_title>Fludarabine ( Fludara® ) Plus Alemtuzumab ( CAMPATH® , MabCampath® ) v Fludarabine Alone B-Cell Chronic Lymphocytic Leukemia ( B-CLL ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>A diagnosis Bcell chronic lymphocytic leukemia ( BCLL ) ; accord National Cancer Institute Working Group ( NCI WG ) criterion . Relapsed refractory disease 1 prior regimen except patient refractory ( i.e. , progress ) fludarabine alemtuzumab therapy . Patients previously respond ( complete response partial response ) fludarabine alemtuzumab therapy , relapse time study entry , may eligible response fludarabine alemtuzumab therapy must last &gt; 12 month ( i.e. , &gt; 12 month document response document relapse ) . Binet stage A , stage B , stage C Rai Stage I IV disease evidence progression evidence presence one following : I . Evidence progressive marrow failure manifest : 1 ) decrease hemoglobin &lt; 11g/dL , 2 ) decrease platelet count &lt; 100 x 10^9/L within previous 6 month , 3 ) decrease absolute neutrophil count ( ANC ) &lt; 1.0 X 10^9/L . II . Progressive splenomegaly &gt; 2 cm leave costal margin organomegaly . III . Progressive lymphadenopathy . IV . Progressive lymphocytosis increase 50 % 2month period , anticipate double time le 6 month . World Health Organization ( WHO ) performance status ( PS ) 0 1 . Life expectancy &gt; 12 week . Anticancer therapy , major surgery , irradiation complete &gt; 3 week randomization study . Patient must recover acute side effect incur result previous therapy . Serum creatinine less equal 2.0 x institutional upper limit normal ( ULN ) calculate creatinine clearance ( CrCl ) great equal 30mL/min use Cockroft Gault formula . Adequate liver function indicate total bilirubin , AST , ALT le equal 2 x institutional ULN value , unless directly attributable patient 's tumor . Female patient childbearing potential must negative serum pregnancy test 2 week first dose study drug ( ) . Male female patient must agree use effective contraceptive method study treatment , appropriate , minimum 6 month follow study therapy . Signed , write informed consent . Previously treat &gt; 1 prior regimen BCLL . Previously treat fludarabine plus alemtuzumab ( FluCAM ) regimen BCLL . Positive Coombs test actively hemolyzing . Absolute neutrophil count ( ANC ) &lt; 1.5 x 10^9/L platelet count &lt; 75 x 10^9/L , unless due bone marrow involvement . Medical condition require chronic use pharmacologic dose oral corticosteroid , i.e . anything replacement dose level . History anaphylaxis follow exposure monoclonal antibody . Use investigational agent within 6 week prior study randomization . Active infection history severe infection ( grade 4 ) within 3 month prior study randomization . Known human immunodeficiency virus ( HIV ) positive . Autoimmune thrombocytopenia . Active second malignancy . Known central nervous system ( CNS ) involvement BCLL . Other severe , concurrent disease , include tuberculosis , mental disorder , serious cardiac functional capacity ( Class III IV define New York Heart Association Classification ) , severe diabetes , severe hypertension , pulmonary disease ( chronic obstructive pulmonary disease [ COPD ] hypoxemia ) , major organ malfunction ( liver , kidney ) could interfere patient 's ability participate study . Pregnant nursing woman . Patients progress aggressive Bcell cancer Richter 's syndrome . Active hepatitis history prior viral hepatitis B hepatitis C , positive hepatitis B serology without prior immunization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>